Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
Page 1
Doc 1402021290.1
The Calmer Co International Limited
ACN 169 441 874
Notice of Annual General Meeting
The Annual General Meeting of the Company will be held at the
offices of HWL Ebsworth Lawyers, at Level 19, 480 Queen St, Brisbane,
Queensland, on Friday, 28 November 2025 at 10:00 a.m. (AEST)
The Notice of Annual General Meeting should be read in its entirety. If Shareholders are in
doubt as to how to vote, they should seek advice from a suitably qualified professional
advisor prior to voting.
Should you wish to discuss any matter, please do not hesitate to contact the
Company Secretary by telephone on +61 7 3844 1010.
Shareholders are encouraged to vote by lodging the proxy form attached to the Notice
Page 2
Doc 1402021290.1
The Calmer Co International Limited
ACN 169 441 874
(Company)
Notice of Annual General Meeting
Notice is given that the annual general meeting of The Calmer Co International Limited will be held at
the offices of HWL Ebsworth Lawyers, at Level 19, 480 Queen St, Brisbane, Queensland, on Friday,
28 November 2025 at 10:00 a.m. (AEST) (Meeting).
The Explanatory Memorandum provides additional information on matters to be considered at the
Meeting. The Explanatory Memorandum and the Proxy Form form part of the Notice.
Terms and abbreviations used in the Notice are defined in Schedule 1.
Agenda
1. Annual Report
To receive and consider the annual financial report of the Company for the financial year
ended 30 June 2025, together with the declaration of the Directors, the Directors’ Report, the
Remuneration Report, and the Auditor’s Report.
No resolution is required to be passed on this item.
2. Resolutions
Resolution 1 – Remuneration Report
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
a non-binding resolution:
“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes,
approval is given for the adoption of the Remuneration Report as contained in the Company’s
annual financial report for the financial year ended 30 June 2025.”
Short Explanation
The Corporations Act provides that a resolution that the remuneration report be adopted must be put
to vote at a listed company’s annual general meeting. The vote on Resolution 1 is advisory only and
does not bind the Directors or the Company.
Resolution 2 – Re-election of Director – Dr Anthony Noble
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That Dr Anthony Noble, who retires by rotation in accordance with Article 11.3 of the
Constitution, Listing Rule 14.5 and for all other purposes, and, being eligible and offering
Page 3
Doc 1402021290.1
himself for re-election, is re-elected as a Director on the terms and conditions in the
Explanatory Memorandum.'
Resolution 3 – Re-election of Director – Mr Griffon Emose
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That Mr Griffon Emose, who retires by rotation in accordance with Article 11.3 of the
Constitution, Listing Rule 14.5 and for all other purposes, and, being eligible and offering
himself for re-election, is re-elected as a Director on the terms and conditions in the
Explanatory Memorandum.'
Resolution 4 – Approval of 10% Placement Facility
To consider and, if thought fit, to pass with or without amendment, as a special resolution the
following:
'That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given
for the Company to issue Equity Securities up to 10% of the fully paid ordinary issued capital
of the Company (at the time of the issue) calculated in accordance with the formula prescribed
in ASX Listing Rule 7.1A2, over a 12 month period from the date of the Meeting, at a price not
less than that determined pursuant to Listing Rule 7.1A.3 and otherwise on the terms and
conditions set out in the accompanying Explanatory Statement.'
Resolution 5 – Ratification of prior issue of Advisor Options
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That the issue of 5,150,000 Advisor Options to Novus Capital Limited (or its nominees) is
approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the
terms and conditions in the Explanatory Memorandum.'
Resolution 6 – Ratification of prior issue of Consideration Shares
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That the issue 28 November 2024 of 5,000,000 Consideration Shares to Sparke Plus Pte Ltd
is approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the
terms and conditions in the Explanatory Memorandum.'
Resolution 7(a) and (b) – Ratification of prior issue of Placement Shares
and Placement Options
To consider and, if thought fit, to pass with or without amendment, each as an ordinary
resolution the following:
'That the issue on 26 March 2025 of:
(a) 955,683 Placement Shares; and
Page 4
Doc 1402021290.1
(b) 477,842 Placement Options,
to Kinetic Growth Fund is approved under and for the purposes of Listing Rule 7.4 and for all
other purposes, on the terms and conditions in the Explanatory Memorandum.'
Resolution 8 – Ratification of prior issue of Advisor Shares
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That the issue of 6,111,167 Advisor Shares to Mustafa Ahmed of Atherton Group is approved
under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms and
conditions in the Explanatory Memorandum.'
Resolution 9 – Ratification of prior issue of Lead Manager Options
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That the issue of 20,014,259 Lead Manager Options to Mahe Capital Pty Ltd is approved
under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms and
conditions in the Explanatory Memorandum.'
Resolution 10 – Ratification of prior issue of Convertible Notes
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes,
Shareholders ratify the issue of 700,000 Convertible Notes under the Tranche 1 Placement,
on the terms and conditions set out in the Explanatory Memorandum.'
Resolution 11 – Approval to issue Convertible Notes
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That, pursuant to and in accordance with Listing Rule 7.1 and for all other purposes,
Shareholders approve the issue of up to 700,000 Convertible Notes under the Tranche 2
Placement on the terms and conditions as set out in the Explanatory Memorandum.'
Resolution 12 – Renewed Approval of Employee Securities Incentive
Plan
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That the existing employee incentive scheme of the Company known as the "Employee
Securities Incentive Plan" last approved at the annual general meeting held 20 November
2023 and the issue of Securities under that plan are approved under and for the purposes of
exception 13(b) of Listing Rule 7.2 and for all other purposes, on the terms and conditions in
the Explanatory Memorandum.'
Page 5
Doc 1402021290.1
Voting exclusions
Pursuant to the Listing Rules, the Company will disregard any votes cast in favour of:
(a) Resolution 4, if at the time of the Meeting, the Company is proposing to make an issue
of Equity Securities under the Placement Facility, by or on behalf of any persons who
are expected to participate in, or who will obtain a material benefit as a result of, the
proposed issue (except a benefit solely by reason of being a Shareholder), or any
associate of those persons;
(b) Resolution 5, Resolution 6, Resolution 7, Resolution 8, Resolution 9, Resolution 10 by
or on behalf of any person who participated in the issue of the Shares and Options or
is a counterparty to the agreement being approved, or any of their respective
associates;
(c) Resolution 11 by or on behalf of any person who is expected to participate in, or who
will obtain a material benefit as a result of, the proposed issue (except a benefit solely
by reason of being a Shareholder) or any of their respective associates;
(d) Resolution 12 by or on behalf of a person who is eligible to participate in the employee
incentive scheme, or any of their respective associates;
The above voting exclusions do not apply to a vote cast in favour of the relevant Resolution
by:
(a) a person as proxy or attorney for a person who is entitled to vote, in accordance with
directions given to the proxy or attorney to vote on the Resolution in that way; or
(b) the Chair as proxy or attorney for a person who is entitled to vote, in accordance with
a direction given to the Chair to vote on the Resolution as the Chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on
behalf of a beneficiary provided the following conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary
is not excluded from voting, and is not an associate of a person excluded from
voting, on the Resolution; and
(ii) the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
Shares held by or for an employee incentive scheme must only be voted on a Resolution
under the Listing Rules if and to the extent that they are held for the benefit of a nominated
participant in the scheme; the nominated participant is not excluded from voting on the
Resolution under the Listing Rules; and the nominated participant has directed how the
Shares are to be voted.
Voting prohibitions
Resolution 1: In accordance with sections 250BD and 250R of the Corporations Act, a vote on
this Resolution must not be cast (in any capacity) by or on behalf of a member of the Key
Management Personnel details of whose remuneration are included in the Remuneration
Report, or a Closely Related Party of such a member.
Page 6
Doc 1402021290.1
A vote may be cast by such person if the vote is not cast on behalf of a person who is
excluded from voting on this Resolution, and:
(a) the person is appointed as a proxy by writing that specifies the way the proxy is to
vote on this Resolution; or
(b) the voter is the Chair and the appointment of the Chair as proxy does not specify the
way the proxy is to vote on this Resolution, but expressly authorises the Chair to
exercise the proxy even if this Resolution is connected with the remuneration of a
member of the Key Management Personnel.
BY ORDER OF THE BOARD
Natalie Climo
Company Secretary
The Calmer Co International Limited
Dated: 29 October 2025
Page 7
Doc 1402021290.1
The Calmer Co International Limited
ACN 169 441 874
(Company)
Explanatory Memorandum
1. Introduction
The Explanatory Memorandum has been prepared for the information of Shareholders in
connection with the business to be conducted at the Meeting to be held at the offices of HWL
Ebsworth Lawyers, at Level 19, 480 Queen St, Brisbane, Queensland, on Friday, 28
November 2025 at 10:00 a.m. (AEST).
The Explanatory Memorandum forms part of the Notice which should be read in its entirety.
The Explanatory Memorandum contains the terms and conditions on which the Resolutions
will be voted.
The Explanatory Memorandum includes information about the following to assist Shareholders
in deciding how to vote on the Resolutions:
Section 2 Voting and attendance information
Section 3 Annual Report
Section 4 Resolution 1 – Remuneration Report
Section 5 Resolution 2 – Re-election of Director – Dr Anthony Noble
Section 6 Resolution 3 – Re-election of Director – Mr Griffon Emose
Section 7 Resolution 4 – Approval of 10% Placement Facility
Section 8 Resolution 5 – Ratification of prior issue of Advisor Options
Section 9 Resolution 6 – Ratification of prior issue of Consideration Shares
Section 10 Resolution 7(a) and (b) – Ratification of prior issue of Placement Shares
and Placement Options
Section 11 Resolution 8 - Ratification of prior issue of Advisor Shares
Section 12 Resolution 9 – Ratification of prior issue of Lead Manager Options
Section 13.6(f) Resolution 10 – Ratification of prior issue of Convertible Notes
Section 14 Resolution 11 – Approval to issue Convertible Notes
Section 15 Resolution 12 – Renewed Approval of Employee Securities Incentive Plan
Schedule 1 Definitions
Page 8
Schedule 2 Terms of issue of Options
Schedule 3 Terms of issue of Convertible Notes
Schedule 4 Summary of Employee Securities Incentive Plan
A Proxy Form is located at the end of the Explanatory Memorandum.
2. Voting and attendance information
Shareholders should read the Notice including the Explanatory Memorandum carefully before
deciding how to vote on the Resolutions.
2.1 Voting in person
In accordance with Rule 19 of the Company’s Constitution, the Chair intends to call a poll on
each of the Resolutions proposed at the Meeting. Each Resolution considered at the Meeting
will therefore be conducted by a poll, rather than on a show of hands. The Chair considers
voting by poll to be in the interests of the Shareholders as a whole and is a way to ensure the
views of as many Shareholders as possible are represented at the Meeting.
Shareholders may vote by appointing a proxy to attend and vote on their behalf, using the
enclosed Proxy Form.
2.2 Voting by proxy
A member who is entitled to vote at the Meeting may appoint:
(a) one proxy if the member is only entitled to one vote; or
(b) two proxies if the member is entitled to more than one vote.
Where the member appoints two proxies, the appointment may specify the proportion or
number of votes that each proxy may exercise. If the appointment does not specify a
proportion or number, each proxy may exercise one half of the votes, in which case any
fraction of votes will be discarded.
A proxy need not be a member of the Company.
The Proxy Form and the power of attorney or other authority (if any) under which it is signed
(or a certified copy) must be received by the Company's Share Registry no later Wednesday,
26 November 2025 at 10:00 a.m. (AEST) (that is, at least 48 hours before the meeting).
Proxies received after this time will not be accepted. Instructions for completing the Proxy
Form are outlined on the form.
Proxies given by corporate Shareholders must be executed in accordance with their
Constitutions or signed by a duly authorised attorney.
A proxy may decide whether to vote on any motion except where the proxy is required by law
or the Constitution to vote, or abstain from voting, in their capacity as a proxy. If a proxy is
directed how to vote on an item of business, the proxy may vote on that item only in
accordance with that direction. If a proxy is not directed how to vote on an item of business, a
proxy may vote how he or she thinks fit.
Page 9
The Constitution provides that a Proxy Form issued by the Company may provide that where
the appointment of a proxy has not identified the person who may exercise it, the appointment
will be deemed to be given in favour of the Chair of the meeting to which it relates or to such
other person as the Board determines.
If a Shareholder appoints the Chair of the meeting as the Shareholder’s proxy and does not
specify how the Chair is to vote on an item of business, the Chair will vote, as a proxy for that
Shareholder, in favour of the item on a poll.
3. Annual Report
In accordance with section 317 of the Corporations Act, Shareholders will be offered the
opportunity to discuss the Annual Report, including the Financial Report, the Directors' Report
and the Auditor's Report for the financial year ended 30 June 2025.
There is no requirement for Shareholders to approve the Annual Report.
At the Meeting, Shareholders will be offered the opportunity to:
(a) discuss the Annual Report which is available online at
https://thecalmerco.com/financial-reports;
(b) ask questions about, or comment on, the management of the Company; and
(c) ask the auditor questions about the conduct of the audit and the preparation and
content of the Auditor's Report.
In addition to taking questions at the Meeting, written questions to the Chair about the
management of the Company, or to the Company's auditor about:
(a) the preparation and content of the Auditor's Report;
(b) the conduct of the audit;
(c) accounting policies adopted by the Company in relation to the preparation of the
financial statements; and
(d) the independence of the auditor in relation to the conduct of the audit,
may be submitted no later than five business days before the Meeting to the Company
Secretary at the Company's registered office.
4. Resolution 1 – Remuneration Report
In accordance with subsection 250R(2) of the Corporations Act, the Company must put the
Remuneration Report to the vote of Shareholders. The Directors' Report contains the
Remuneration Report which sets out the remuneration policy for the Company and the
remuneration arrangements in place for the executive Directors, specified executives and non-
executive Directors.
In accordance with subsection 250R(3) of the Corporations Act, Resolution 1 is advisory only
and does not bind the Directors. If Resolution 1 is not passed, the Directors will not be
required to alter any of the arrangements in the Remuneration Report.
Page 10
If the Company's Remuneration Report receives a 'no' vote of 25% or more (Strike) at two
consecutive annual general meetings, Shareholders will have the opportunity to remove the
whole Board, except the managing director (if any).
Where a resolution on the Remuneration Report receives a Strike at two consecutive annual
general meetings, the Company will be required to put to Shareholders at the second annual
general meeting a resolution on whether another meeting should be held (within 90 days) at
which all Directors (other than the managing director, if any) who were in office at the date of
approval of the applicable Directors' Report must stand for re-election.
The Company's Remuneration Report did not receive a Strike at the 2024 annual general
meeting.
The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about, or
make comments on the Remuneration Report.
Resolution 1 is an ordinary resolution.
Given the material personal interests of all Directors in this Resolution, the Board makes no
recommendation to Shareholders regarding this Resolution.
5. Resolution 2 – Re-election of Director – Dr Anthony Noble
5.1 General
The Company's Constitution provides that at the annual general meeting one-third of the
Directors for the time being must retire from office, provided always that no Director except a
Managing Director shall hold office for a period in excess of 3 years, or until the third annual
general meeting following his or her appointment, whichever is the longer, without submitting
himself for re-election. This is consistent with ASX Listing Rules 14.4 and 14.5.
The Directors to retire at an annual general meeting are those who have been longest in office
since their last election. A retiring Director is eligible for re-election.
Dr Anthony Noble, having transitioned from Managing Director of the Company to Non-
Executive Director of the Company on 1 March 2025, will retire in accordance with the
Constitution and relevant ASX Listing Rules, and being eligible, seeks re-election.
If Resolution 2 is passed, Dr Noble will be appointed as a Non-Executive Director of the
Company.
If Resolution 2 is not passed, Dr Noble will not be appointed as a Director and will retire at the
end of the Meeting.
5.2 Qualifications and other material directorships
Dr Noble joined the Company as Chief Executive Officer on 31 May 2021, and became the
Company's Managing Director from 20 December 2021. Prior to this he was CEO of
Australian Biotherapeutics, a manufacturer of live biotherapeutics based in Coolum Beach,
Queensland. Dr Noble worked at SFI Health and held roles as Managing Director of SFI
Research Pty Ltd, as Global Head of Innovation, Group Head of North Asia and as General
Manager of the SFI-Shineway Chinese Joint Venture. Anthony was Principal Scientist, for
Cryosite Ltd and a lead inspector for the Human Tissue Authority (UK).
Page 11
Dr Noble is currently also a Non-Executive Director of Aumake Limited (ASX:AUK).
5.3 Board recommendation
Resolution 2 is an ordinary resolution.
The Board (other than Dr Noble) recommends that Shareholders vote in favour of Resolution 2
on the basis that Dr Noble's skills and experience have and will continue to support the
Company in achieving its strategic objectives.
6. Resolution 3 – Re-election of Director – Mr Griffon Emose
6.1 General
The Company's Constitution provides that at the annual general meeting one-third of the
Directors for the time being must retire from office, provided always that no Director except a
Managing Director shall hold office for a period in excess of 3 years, or until the third annual
general meeting following his or her appointment, whichever is the longer, without submitting
himself for re-election. This is consistent with ASX Listing Rules 14.4 and 14.5.
The Directors to retire at an annual general meeting are those who have been longest in office
since their last election. A retiring Director is eligible for re-election.
Mr Griffin Emose, having been appointed as Non-Executive Director of the Company on 30
January 2023, will retire in accordance with the Constitution and relevant ASX Listing Rules,
and being eligible, seeks re-election.
If Resolution 3 is passed, Mr Emose will be appointed as an Executive Chairman of the
Company.
If Resolution 3 is not passed, Mr Emose will not be appointed as a Director and will retire at
the end of the Meeting.
6.2 Qualifications and other material directorships
Mr Emose Griffon is a Fijian citizen and the Managing Director of Kontiki Capital. He was
previously the Manager Public Awareness & Investor Education at the Capital Markets
Development Authority and an economist at the Ministry of Finance where he served with the
Economic Policy Analysis Unit and the Financial Management Reform Project. He is licensed
by the Reserve Bank of Fiji as an Investment Adviser Representative and serves on several
other Boards.
Past Directorships include for the South Pacific Stock Exchange, Fiji Gas and Pleass Global.
Griffon graduated with a Bachelor of Commerce from the University of Auckland, New Zealand
and completed the Graduate Diploma in Applied Finance & Investment through the Securities
Institute of Australia (now the Financial Services Institute of Australasia). He is a member of
the CFA Institute and earned the CFA Charter in 2005.
6.3 Board recommendation
Resolution 3 is an ordinary resolution.
Page 12
The Board (other than Mr Emose) recommends that Shareholders vote in favour of Resolution
3 on the basis that Mr Emose's skills and experience have and will continue to support the
Company in achieving its strategic objectives.
7. Resolution 4 – Approval of 10% Placement Facility
7.1 General
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
Equity Securities that a listed company can issue without the approval of its shareholders over
any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of
that period.
Under Listing Rule 7.1A, however, an eligible entity can seek approval from its members, by
way of a special resolution passed at its annual general meeting, to increase this 15% limit by
an extra 10% to 25% (Placement Facility).
Resolution 4 seeks Shareholder approval by way of a special resolution to provide the
Company the ability to issue Equity Securities under the Placement Facility during the
Placement Period (refer to Section (e) below). The number of Equity Securities to be issued
under the Placement Facility will be determined in accordance with the formula prescribed in
Listing Rule 7.1A.2 (refer to Section (c) below).
If Resolution 4 is passed, the Company will be able to issue Equity Securities up to the
combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.
If Resolution 4 is not passed, the Company will not be able to access the additional 10%
capacity to issue Equity Securities without Shareholder approval provided for in Listing
Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without
Shareholder approval set out in Listing Rule 7.1.
7.2 Listing Rule 7.1A
(a) Is the Company an eligible entity?
An 'eligible entity' means an entity which is not included in the S&P/ASX 300 Index
and which has a market capitalisation of $300 million or less.
The Company is an eligible entity for these purposes as it is not included in the
S&P/ASX 300 Index and has a market capitalisation of approximately $9.18 million,
based on the closing price of Shares $0.003 on 9 October 2025.
(b) What Equity Securities can be issued?
Any Equity Securities issued under the Placement Facility must be in the same class
as an existing quoted class of Equity Securities of the eligible entity.
As at the date of the Notice, only the Company's fully paid ordinary shares are quoted.
(c) How many Equity Securities can be issued?
If Shareholders approve Resolution 4, the number of Equity Securities the Company
may issue under the Placement Capacity will be determined in accordance with the
formula prescribed in ASX Listing Rule 7.1A.2.
Page 13
(d) At what price can the Equity Securities be issued?
Any Equity Securities issued under Listing Rule 7.1A must be issued for a cash
consideration per security which is not less than 75% of the VWAP of Equity
Securities in the same class calculated over the 15 Trading Days on which trades in
that class were recorded immediately before:
(i) the date on which the price at which the Equity Securities are to be issued is
agreed by the Company and the recipient of the Equity Securities; or
(ii) if the Equity Securities are not issued within 10 Trading Days of the date in the
paragraph above, the date on which the Equity Securities are issued,
(Minimum Issue Price).
(e) When can Equity Securities be issued?
Shareholder approval of the Placement Facility under Listing Rule 7.1A will be valid
from the date of the Meeting and will expire on the earlier to occur of:
(i) the date that is 12 months after the date of the Meeting;
(ii) the time and date of the Company's next annual general meeting; or
(iii) the date of Shareholder approval of a transaction under Listing Rules 11.1.2
(a significant change to the nature or scale of activities) or 11.2 (disposal of
main undertaking),
(Placement Period).
(f) What is the effect of Resolution 4?
The effect of Resolution 4 will be to allow the Directors to issue the Equity Securities
under Listing Rule 7.1A during the Placement Period without further Shareholder
approval or using the Company's 15% annual placement capacity under Listing
Rule 7.1.
7.3 Specific information required by Listing Rule 7.3A
Under and for the purposes of Listing Rule 7.3A, the following information is provided in
relation to the Placement Facility:
(a) Final date for issue
The Company will only issue the Equity Securities under the Placement Facility during
the Placement Period (refer to Section (e) above).
Shareholder approval of the Placement Facility will cease to be valid if Shareholders
approve a transaction under Listing Rule 11.1.2 or 11.2.
(b) Minimum issue price
Where the Company issues Equity Securities under the Placement Facility, it will only
do so for cash consideration and the issue price will be not less than the Minimum
Issue Price (refer to Section (d) above).
Page 14
(c) Purposes of issues under Placement Facility
The Company may seek to issue Equity Securities under the Placement Facility for
the purposes of raising funds for continued investment in the Company's current
assets, the acquisition of new assets or investments (including expenses associated
with such an acquisition) and/or for general working capital.
The Company will comply with the disclosure obligations under Listing Rules 7.1A.4
and 3.10.3 upon issue of any Equity Securities.
(d) Risk of economic and voting dilution
Shareholders should note that there is a risk that:
(i) the market price for the Company's Equity Securities may be significantly
lower on the date of the issue of the Equity Securities than on the date of the
Meeting; and
(ii) the Equity Securities may be issued at a price that is at a discount to the
market price for the Company's Equity Securities on the issue date,
which may have an effect on the amount of funds raised by the issue of the Equity
Securities.
If Resolution 4 is approved by Shareholders and the Company issues Equity
Securities under the Placement Facility, the existing Shareholders' economic and
voting power in the Company may be diluted as shown in the table below (in the case
of Options, only if the Options are converted into Shares).
The table below shows the dilution of existing Shareholders based on an issue price of
$0.003 per Share which was the closing price of the Company’s Shares on the ASX
on 9 October 2025 and the current number of Shares for 'A' calculated in accordance
with the formula in Listing Rule 7.1A.2 on 9 October 2025 (Variable A), with:
(i) two examples where Variable A has increased, by 50% and 100%; and
(ii) two examples of where the issue price of Shares has decreased by 50% and
increased by 100% as against the current market price.
Page 15
Share on issue
(Variable A in
Listing Rule
7.1A.2)
Dilution
Issue price per
Share
0.002
50% decrease
in Current
Market Price
$0.004
Current Marke
Share your feedback
Discover